Simplex Trading’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Simplex Trading’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-670	Closed	-$14K	–	11149
2022 Q2	$14K	Sell	670 -30	-4%	-$704	﹤0.01%	8000
2022 Q1	$26K	Buy	700 +530	+312%	+$18.3K	﹤0.01%	7959
2021 Q4	$9K	Sell	170 -265	-61%	-$17.8K	﹤0.01%	9154
2021 Q3	$41K	Hold	435	–	–	﹤0.01%	7771
2021 Q2	$41K	Buy	+435	New	+$48K	﹤0.01%	7903
2021 Q1	–	Sell	-1	Closed	-$181	–	8402
2020 Q4	$17K	Buy	+1	New	+$162	﹤0.01%	7094
2017 Q2	–	Hold	0	–	-$2K	–	6954
2017 Q1	–	Hold	0	–	–	–	5392
2016 Q4	–	Sell	-1	Closed	-$1K	–	6704
2016 Q3	$1K	Buy	+1	New	+$1.08K	﹤0.01%	5490
2016 Q2	–	Hold	0	–	–	–	4739
2016 Q1	–	Sell	-1	Closed	-$1.43K	–	3496
2015 Q4	$62K	Buy	+1	New	+$1.53K	﹤0.01%	1758
2015 Q3	–	Hold	0	–	–	–	3569
2015 Q2	–	Sell	-1	Closed	-$1.08K	–	4400
2015 Q1	$5K	Buy	+1	New	+$3.3K	﹤0.01%	3558

Other funds holding NBSE

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Simplex Trading's NBSE Position: Q2 2023 in Review

Simplex Trading sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2023, closing a stake of 86 shares.

Simplex Trading first reported a position in NBSE in Q1 2015 and held it in 18 quarters. The position peaked at $120K in Q1 2021. 27 funds tracked by Wall St. Rank hold NBSE as of Q2 2023.

Simplex Trading reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Simplex Trading sold 86 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2023.
Simplex Trading first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2015 and held it in 18 quarters.
Simplex Trading's NeuBase Therapeutics, Inc. Common Stock position peaked at $120K in Q1 2021.
27 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Simplex Trading's 13F filing for Q2 2023, filed 4 Aug 2023.